

Vanucizumab

Cat. No.:	HY-P99330
CAS No.:	1448221-05-3
Target:	VEGFR; Tie
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects ^[1] .								
In Vivo	Vanucizumab (20 mg/kg; i.p.; once weekly; for 6 weeks) shows tumor growth inhibition and induces tumor stasis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>SCID beige mice bearing Colo205 cells^[2]</td></tr><tr><td>Dosage:</td><td>20 mg/kg</td></tr><tr><td>Administration:</td><td>i.p.; once weekly; for 6 weeks</td></tr><tr><td>Result:</td><td>Showed tumor growth inhibition.</td></tr></table>	Animal Model:	SCID beige mice bearing Colo205 cells ^[2]	Dosage:	20 mg/kg	Administration:	i.p.; once weekly; for 6 weeks	Result:	Showed tumor growth inhibition.
Animal Model:	SCID beige mice bearing Colo205 cells ^[2]								
Dosage:	20 mg/kg								
Administration:	i.p.; once weekly; for 6 weeks								
Result:	Showed tumor growth inhibition.								

REFERENCES

[1]. Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545.

[2]. Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA